An effective tumor-inhibiting siRNA delivery platform

Area of Science:

• Biotechnology
• Oncology
• Molecular Biology

Background:

• Histidine-lysine (HK) peptides can deliver siRNA, targeting tumor-specific receptors like Neuropilin-1 (NRP-1).
• NRP-1 is overexpressed in aggressive tumors, including triple-negative breast cancer (TNBC).

Purpose of the Study:

• To evaluate the antitumor efficacy of an HK peptide-siRNA delivery system against TNBC.
• To assess the targeting of oncogenes Raf-1 and PD-L1 using this system in vivo.

Main Methods:

• Systemic delivery of HK peptide polyplexes carrying siRaf-1 or siPD-L1 to MDA-MB-231 tumor-bearing athymic mice.
• Tumor size measurement and protein level analysis (Raf-1, PD-L1) post-treatment.
• Monitoring of animal weight as an indicator of systemic toxicity.

Main Results:

• siRaf-1 and siPD-L1 polyplexes reduced tumor volume by 75% and 82%, respectively, compared to siControl.
• Tumor size reduction correlated with decreased Raf-1 and PD-L1 protein expression.
• No significant weight loss was observed in treated groups, indicating good tolerability.

Conclusions:

• HK peptide polyplexes are a promising platform for targeted siRNA delivery in TNBC.
• This system demonstrates significant antitumor activity and warrants further clinical development.
• Targeting oncogenes like Raf-1 and PD-L1 with siRNA offers a viable therapeutic strategy.